52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Piratvisuth, Teerha ^a   Komolmit, Piyawat ^b   Tanwandee, Tawesak ^c   Sukeepaisarnjaroen, Wattana ^d   Chan, Henry L Y ^e   Pessôa, Mário G ^f   Fassio, Eduardo ^g   Ono, Suzane K ^f   Bessone, Fernando ^h   Daruich, Jorge ⁱ   Zeuzem, Stefan ^j   Cheinquer, Hugo ^k   Pathan, Rashidkhan ^l   Dong, Yuhong ^l   Trylesinski, Aldo ^l  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d KHON KAEN UNIVERSITY   (Thailand)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

^h UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

ⁱ HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^j UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^k HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^l NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADJUVANT THERAPY; ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; RHINOPHARYNGITIS; SEROCONVERSION; SIDE EFFECT; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS INHIBITION; VOMITING;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; THYMIDINE; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84873515176     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054279     Document Type: Article

References (30)

1. McMahon BJ, (2005) Epidemiology and natural history of hepatitis B. Semin Liver Dis. 25(Suppl 1): 3-8.
2. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, et al. (2007) Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 12: 1295-1303.
3. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, et al. (2009) Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49: 1503-1514.
4. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, et al. (2004) Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48: 3498-3507.
5. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, et al. (2009) 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 136: 486-495.
6. Yang H, Qi X, Sabogal A, Miller M, Xiong S, et al. (2005) Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 10: 625-633.
7. Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, et al. (2004) Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 66: 1153-1158.
8. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, et al. (2007) Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 147: 745-754.
9. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, et al. (2009) Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 49: 72-79.
10. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, et al. (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 359: 2442-2455.
11. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505.
12. Chen CJ, Yang HI, Iloeje UH, (2009) Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 49: S72-S84.
13. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F, (2003) Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 37: 1309-1319.
14. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, et al. (2001) Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34: 785-791.
15. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, et al. (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 357: 2576-2588.
16. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, et al. (2007) Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 5: 890-897.
17. European Association For The Study Of The Liver, (2009) EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 50: 227-242.
18. Lok AS, McMahon BJ, (2007) Chronic hepatitis B. Hepatology. 45: 507-539.
19. Cockcroft DW, Gault MH, (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
20. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis 39: S76-S110.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470.
22. Jia JD, Hou JL, Yin YK, Xu DZ, Tan DM, et al. (2007) [The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]. Zhonghua Gan Zang Bing Za Zhi 15: 342-345.
23. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, et al. (2009) Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 51: 11-20.
24. Andersson KL, Chung RT, (2009) Monitoring during and after antiviral therapy for hepatitis B. Hepatology. 49: S166-S173.
25. Liaw YF, Chu CM, (2009) Hepatitis B virus infection. Lancet 373: 582-592.
26. Gane EJ, Chan HL, Choudhuri G, Suh DJ, Chutaputti A, et al. (2010) Treatment of decompensated HBV-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine [Abstract]. J Hepatol (Suppl. 1): S4.
27. Gane EJ, Deray G, Piratvisuth T, Chan HL, Zeuzem S, et al. (2011) Renal function is improved for Chronic Hepatitis B (CHB) patients treated with telbivudine [Abstract]. Hepatol (Suppl. 1): 1044A-1045A.
28. van Bömmel F, de Man R, Ferenci P, Bronowiki JP, Fülöp B, et al. (2009) Long-term follow-up evaluation of the efficacy and safety of tenofovir disoproxil fumarate (TDF) in a European multicenter (nucleos(t)ide experienced) hepatitis B virus HBV-infected cohort. 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA; Oct 30- Nov 3, 2009 [Abstract 221]. Available: http://www.hivandhepatitis.com/2009icr/aasld/posters/vanBommel.ppt. Accessed 2012 Jul 31.
29. Gish RG, Mangahas MF, Baqai SF, Shaw RE, Clark MD, et al. (2010) Risk of renal toxicity with tenofovir DF (TFD) for chronic hepatitis B (CHB) [Abstract]. Hepatol 52(Suppl. 1): 529A.
30. Mauss S, Berger F, Filmann N, Hueppe D, Henke J, et al. (2011) Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 55: 1235-1240.